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Objective: Delays in achieving blood pressure (BP) control may increase morbidity and 
mortality in patients with hypertension. Thus, deciding which antihypertensive agent to use 
and at what dosage, in addition to determining when to initiate combination therapy and which 
agents to combine, is important for achieving BP control.
Methods: This randomized, double-blind, 14-week study was conducted to compare the 
efficacy and tolerability of various doses of valsartan ± hydrochlorothiazide (HCTZ) versus 
amlodipine ± HCTZ for maximizing BP control in 1,285 patients with uncontrolled hypertension. 
Patients with stage 1 hypertension and naïve to antihypertensive therapy (33.9%) started 
valsartan 160 mg or amlodipine 5 mg. Treatment-naïve patients with stage 2 hypertension 
(13.5%) or those uncontrolled on current antihypertensive monotherapy (52.6%) started 
valsartan 160 mg/HCTZ 12.5 mg or amlodipine 10 mg. At weeks 4, 8, and 11, patients not 
achieving BP control were up-titrated (maximum: valsartan 320 mg/HCTZ 25 mg, amlodipine 
10 mg/HCTZ 25 mg).
Results:  At study end, 78.8% of patients on valsartan ± HCTZ were controlled (BP  140/90 mmHg) 
and still on study medication versus 67.8% on amlodipine ± HCTZ (P  0.0001). Amlodipine-
treated patients had a higher incidence of peripheral edema (22.4% vs 2.2%) and associated 
discontinuations (7.3% vs 1%). Initiating therapy earlier with valsartan/HCTZ, rather than 
titrating monotherapy to its maximum dose before adding a second agent, was superior to 
amlodipine monotherapy or amlodipine ± HCTZ for achieving BP control, and avoided excessive 
treatment adjustments and maintained tolerability.
Keywords: efficacy, hydrochlorothiazide, hypertension, combination therapy, titration, 
tolerability
Introduction
Numerous studies have demonstrated the importance of achieving blood pressure 
(BP) control in patients with hypertension.1 Delays in reaching BP goals may be 
associated with increased cardiovascular morbidity and mortality. Thus, determining 
which antihypertensive agent to use, and at what dosage, is important. Moreover, 
because most of the hypertensive population will require multiple drugs to attain BP 
control,2,3 physicians must determine when to initiate combination antihypertensive 
therapy (both in treatment-naïve patients and those on monotherapy) and must decide 
which antihypertensive agents are best to use in combination. Early use of combination 
antihypertensive therapy is associated with greater reductions in BP and earlier 
achievement of BP control, and is recommended as initial treatment for patients with 
BP  160/100 mmHg or high cardiovascular risk.2,3Vascular Health and Risk Management 2009:5 884
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The angiotensin-receptor blocker (ARB) valsartan and the 
calcium-channel blocker (CCB) amlodipine have proven to 
be safe and effective antihypertensive agents when used as 
monotherapy.4–7 The use of a thiazide diuretic in combination 
with an ARB or CCB is a commonly recommended option 
for the many patients who require more than a single 
antihypertensive agent.2,3 The addition of hydrochlorothiazide 
(HCTZ) to valsartan, for example, has been shown to 
provide greater antihypertensive efficacy than that of the 
individual components and to be well tolerated.8 Further, 
this combination has demonstrated safety and efficacy for 
the initial treatment of hypertension.9 The combination of 
valsartan ± HCTZ at a low dose (80–160/12.5 mg) also has 
demonstrated similar reductions in BP to a maximum dose of 
amlodipine.10–13 Titrating the combination of valsartan/HCTZ 
to its maximum dose may be more effective than adding 
HCTZ after the patient has reached the maximum dose of 
amlodipine.14
The study described herein compared the efficacy 
and tolerability of two strategies for maximizing BP 
control (140/90 mmHg) in patients with uncontrolled 
hypertension: early initiation of the combination of a 
renin–angiotensin system (RAS) blocker with a thiazide 
diuretic (valsartan ± HCTZ) compared to a strategy of titrating 
monotherapy, using amlodipine, to maximum dose and then 
adding a second antihypertensive agent (HCTZ). To more 
closely mimic clinical practice, the study did not include a 
washout period (background medications were discontin-
ued at baseline) or placebo run-in. Instead, eligible patients 
were immediately switched from their current antihyperten-
sive therapy to study medication, including direct initiation 
of combination therapy (valsartan/HCTZ) or direct initiation 
with maximal dose (amlodipine) in appropriate patients.
Methods
The study protocol was approved by the Independent 
Ethics Committee or Institutional Review Board for each 
center, and the study was conducted in accordance with the 
ethical principles of the Declaration of Helsinki. All patients 
provided written informed consent prior to randomization.
Patients
Eligible patients were aged between 18 and 75 years. 
Treatment-naïve patients had stage 1/grade 1 hypertension 
(mean sitting systolic blood pressure [MSSBP] 140–159 mmHg 
and/or mean sitting diastolic blood pressure [MSDBP] 
90–99 mmHg) or stage 2/grade 2 hypertension (MSSBP 
160–179 mmHg and/or MSDBP 100–109 mmHg).2,3 Patients 
were considered treatment-naïve if they had received no 
antihypertensive medication in the previous 12 weeks. Patients 
on antihypertensive monotherapy were eligible provided 
their BP was uncontrolled (MSSBP 140–160 mmHg and/or 
MSDBP 90–100 mmHg) and they had been on monotherapy 
for 4 weeks and until 2 days before a pre-randomization 
visit. Both treatment-naïve and treated patients had to fulfill 
the BP criteria at both the pre-randomization visit and before 
randomization on day 1.
Key  exclusion  criteria  included  the  following: 
MSSBP  180 mmHg or MSDBP  110 mmHg at any 
time between the pre-randomization visit and day 1; current 
treatment with a CCB; history of hypersensitivity to any of the 
study drugs; cerebrovascular accident or myocardial infarction 
within the previous 12 months or transient ischemic cerebral 
attack within the previous 6 months; presence of congestive 
heart failure, angina pectoris, significant valvular heart disease 
or arrhythmia, second or third degree heart block without a 
pacemaker, or diabetes; history of malignancy within the 
previous five years (except localized basal cell carcinoma 
of the skin); serum potassium level 3.5 or 5.5 mmol/L 
without medication; serum creatinine level 1.5 times above 
the upper limit of normal or a history of dialysis or nephrotic 
syndrome; and alanine or aspartate aminotransferase 
levels 2 times above the upper limit of normal or history 
of hepatic encephalopathy, esophageal varices, or portoca-
val shunt. Women were postmenopausal, surgically sterile, 
or using an adequate method of contraception.
study design
This was a randomized, double-blind, parallel-group, 
active-controlled study conducted in 11 countries (Argentina, 
Brazil, Columbia, Denmark, Ecuador, Spain, Finland, 
Germany, Ireland, Italy, and United Kingdom). Patients were 
assessed for eligibility within two weeks before randomization. 
Patients continued their antihypertensive medication during 
this period. Eligible patients were randomized in a 1:1 ratio 
and directly switched from their current antihypertensive 
therapy to either a valsartan strategy or an amlodipine strategy 
(Figure 1). Stage 1 treatment-naïve patients were started 
on either valsartan 160 mg once daily (o.d.) or amlodipine 
5 mg o.d., whereas stage 2 treatment-naïve patients and 
those uncontrolled on current antihypertensive monotherapy 
were started on valsartan 160 mg/HCTZ 12.5 mg o.d. or 
amlodipine 10 mg o.d. Patients were instructed to take their 
study medication at approximately 8:00 am. To maintain 
blinding, all study medication was identical in packaging, 
labeling, appearance, and odor.Vascular Health and Risk Management 2009:5 885
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Patients visited the clinic at three- to four-week intervals 
during the 14-week treatment period for efficacy and 
tolerability assessments. As shown in Figure 1, up-titration 
or the addition of HCTZ was mandatory at visits in which 
the patient did not achieve a MSSBP  140 mmHg and a 
MSDBP  90 mmHg. Down-titration to the previous step 
was permitted for a MSSBP  100 mmHg or if the patient 
presented with symptomatic hypotension.
Use of monoamine oxidase inhibitors and tricyclic 
antidepressants was prohibited during the study, as was 
the chronic use of oral steroids, sympathomimetic drugs, 
and bronchodilators. Thyroid medication and hormone 
replacement therapy were allowed only if stable maintenance 
doses had been used in the previous six months.
Efficacy assessments
At each clinic visit, sitting BP measurements were 
obtained using a calibrated standard sphygmomanometer 
in accordance with the American Heart Association (AHA) 
Committee Report on blood pressure determination.15 
Blood pressure readings were taken just before ingesting 
the morning dose of study medication (ie, at trough). After 
sitting for five minutes, three consecutive BP measurements 
were taken at one- to two-minute intervals. If the three 
MSSBP readings were not within ± 5 mmHg, the proce-
dure was repeated until this criterion was met. The primary 
efficacy variable was the percentage of patients who 
achieved BP control (MSSBP/MSDBP  140/90 mmHg) 
and were still on study medication at the end of the study 
(week 14).
Tolerability assessments
Adverse events (AEs) were monitored throughout the study 
and included spontaneous reports by the investigators and 
patients. In addition, standard laboratory tests (hematology 
and blood chemistry), vital signs, and physical examinations 
were performed.
statistical methods
Efficacy analyses were performed using the intent-to-
treat (ITT) population, which included all randomized 
patients who received 1 dose of study medication and 
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Figure 1 study design.
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had 1 postbaseline efficacy assessment. The safety 
population included all patients who received 1 dose 
of study medication and had 1 postbaseline tolerability 
assessment.
Demographic and baseline characteristics were 
compared between the two treatment strategies using the 
t-test (continuous variables) or chi-square test (categorical 
variables). For the primary efficacy variable, a logistic 
regression model was fitted including terms for treatment, 
country, and stage of hypertension or failed antihypertensive 
monotherapy. The number and percentage of patients whose 
BP was controlled and who were still on study medication 
within each treatment strategy, the point estimate for the 
odds ratio (valsartan/amlodipine), and the two-sided 95% 
confidence interval (CI) for the odds ratio were determined. 
The change from baseline to each visit and endpoint (week 14 
or last observation carried forward value) in MSSBP and 
MSDBP was analyzed using analysis of covariance. 
Treatment, country, and stage of hypertension or failed 
antihypertensive monotherapy were included as fixed factors 
and baseline BP was included as a covariate in the model. 
The least-squares mean changes from baseline, treatment 
difference, 95% CI for the treatment difference, and P-value 
were determined.
Results
Patients
Patient disposition is presented in Figure 2. Of the 
1,472 patients screened, 1,285 were randomized (641 valsartan, 
644 amlodipine) and 1,125 completed the study (595 valsartan, 
530 amlodipine). The ITT population was used for the primary 
analysis and comprised 1263 patients (632 valsartan, 631 
amlodipine). There were more discontinuations with the 
amlodipine ± HCTZ strategy (114 patients, 17.7%) than with 
the valsartan ± HCTZ strategy (46 patients, 7.2%), primarily due 
to AEs (69 patients [10.7%] vs 22 patients [3.4%], respectively) 
and mostly attributed to peripheral edema (46 patients [7.3%] vs 
two patients [1%]).
Demographic and baseline characteristics were well 
balanced between the two treatment strategies, and no 
statistically significant differences were observed (Table 1). 
The study was conducted in 11 countries (seven in Europe 
Screened
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(n = 187)
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(N = 1285)
Valsartan strategy
(n = 641)
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(n = 644)
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•  Withdrew consent (n = 7)
•  Administrative problems (n = 6)
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   result (n = 3)
•  Lost to follow-up (n = 3)
•  Unsatisfactory therapeutic
   effect (n = 1)
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and four in South America) at 122 research centers. 
Overall, mean age was 54.5 years and mean body mass 
index was 28.4 kg/m2. Most patients were male (55.2%), 
and the majority was Caucasian (86.2%). Patients were 
either stage 1 treatment naïve (33.9%), stage 2 treatment 
naïve (13.5%), or uncontrolled on current antihypertensive 
monotherapy (52.6%). At baseline, MSSBP/MSDBP was 
150.2/93.9 mmHg.
Blood pressure measurements
At week 14, 78.8% of patients in the valsartan ± HCTZ group 
and 67.8% in the amlodipine ± HCTZ group had their BP 
controlled and were still on study medication (P  0.0001) 
(Figure 3). As shown in Figure 3, significant differences in 
favor of valsartan ± HCTZ also were apparent at weeks 8 
(P = 0.0252) and 11 (P = 0.0004). More than 50% of patients 
had their BP controlled and were still on study medication 
by the time of their first on-therapy visit at week 4 (58.1% 
valsartan, 53.9% amlodipine; P = 0.1235).
Among patients who were uncontrolled on current 
antihypertensive monotherapy at the start of the study, 
a significantly greater percentage in the valsartan ± 
HCTZ group (79.4%) than in the amlodipine ± HCTZ 
group (62.9%) achieved BP control and were still 
on study medication at week 14 (P  0.0001). The 
corresponding results for treatment-naïve patients, stage 1 
and stage 2, (78.2% vs 73.5%) also tended to be better for 
valsartan ± HCTZ, but were not statistically superior to 
amlodipine ± HCTZ.
Least-squares mean reductions from baseline in MSSBP 
and MSDBP are shown in Table 2. Substantial reductions 
in MSSBP/MSDBP were apparent by week 4 with both 
treatment strategies (15.3/8.9 mmHg with valsartan, 
13.5/8.0 mmHg with amlodipine). The magnitude of 
Table 1 Demographic and baseline characteristics
Variable Valsartan strategy
(n = 641)
Amlodipine strategy
(n = 644)
Total
(n = 1285)
Mean (sD) age, y 54.6 (10.8) 54.3 (11.3) 54.5 (11.1)
Age group, n (%)
  65 y 505 (78.8) 505 (78.4) 1,010 (78.6)
  65 y 136 (21.2) 139 (21.6) 275 (21.4)
Gender, n (%)
  Male 362 (56.5) 347 (53.9) 709 (55.2)
  Female 279 (43.5) 297 (46.1) 576 (44.8)
Race, n (%)
  caucasian 557 (86.9) 551 (85.6) 1,108 (86.2)
  native American 16 (2.5) 21 (3.3) 37 (2.9)
  Black 10 (1.6) 17 (2.6) 27 (2.1)
  Other 58 (9.0) 55 (8.5) 113 (8.8)
Mean (sD) height, cm 168.6 (10.0) 168.6 (10.2)* 168.6 (10.1)†
Mean (sD) weight, kg 80.9 (15.8) 81.0 (16.7)* 80.9 (16.2)†
Mean BMi, kg/m2 28.4 (4.6) 28.4 (5.0)* 28.4 (4.8)†
serum creatinine, umol/L 79.4 (16) 78.8 (15) 79.1 (16)
serum glucose, mmol/L 5.56 (0.8) 5.55 (0.8) 5.55 (0.8)
serum potassium, mmol/L 4.38 (0.4) 4.35 (0.8) 4.36 (0.8)
MssBP (sD), mmHg 150.4 (9.0) 150.0 (8.9) 150.2 (9.0)
MsDBP (sD), mmHg 93.9 (6.4) 93.8 (6.2) 93.9 (6.3)
stage 1 treatment-naïve, n (%) 220 (34.3) 215 (33.4) 435 (33.9)
stage 2 treatment-naïve, n (%) 90 (14.0) 84 (13.0) 174 (13.5)
Uncontrolled on current monotherapy, n (%) 331 (51.6) 345 (53.6) 676 (52.6)
Note: *n = 640; †n = 1281.
Abbreviations: BMi, body mass index; MsDBP, mean sitting diastolic blood pressure; MssBP, mean sitting systolic blood pressure; sD, standard deviation.Vascular Health and Risk Management 2009:5 888
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reduction was significantly greater with valsartan ± HCTZ at 
weeks 4, 8, 11, and endpoint for MSSBP and at weeks 4, 8, 
and endpoint for MSDBP (all P  0.05).
Titration steps
A numerically similar percentage of patients in each treatment 
strategy were up-titrated over the course of the study. 
At week 11, the last up-titration visit, the majority of stage 1 
treatment-naïve patients were on their initial treatment or the 
first titration step: valsartan 160 mg alone or in combination 
with HCTZ 12.5 mg o.d. (192/219, 87.7%) or amlodipine 
5 mg or 10 mg o.d. (167/215, 77.7%) (Figure 4). At the 
same time point, most stage 2 treatment-naïve patients and 
those uncontrolled on current antihypertensive monotherapy 
also were receiving their initial treatment or the first titration 
step: valsartan 160 mg in combination with either HCTZ 
12.5 mg or 25 mg o.d. (293/413, 70.9%) or amlodipine 10 mg 
alone or in combination with HCTZ 12.5 mg o.d. (253/419, 
60.4%). More patients were on combination treatment with 
valsartan/HCTZ than with amlodipine/HCTZ (Figure 4).
Tolerability
Overall, AEs occurred in 41.5% and 53.3% of patients receiving 
valsartan ± HCTZ and amlodipine ± HCTZ, respectively. 
The most commonly reported AEs were peripheral edema 
(2.2% for valsartan vs 22.4% for amlodipine), headache 
(4.0%, 6.2%), and dizziness (3.8%, 1.7%). Peripheral edema 
resulted in the discontinuation of 46 (7.3%) patients treated 
with amlodipine ± HCTZ compared with two (1.0%) 
patients on valsartan ± HCTZ. The incidence of all AE 
reports of edema is presented by clinic visit in Table 3. There 
were no deaths during the study. Mean changes in laboratory 
findings were minimal. Few patients experienced increases 
in serum creatinine levels 175 µmol/L (two valsartan, 
zero amlodipine) or serum potassium levels 5.8 mmol/L 
(four valsartan, two amlodipine). Twenty-four (3.8%) patients 
in the valsartan ± HCTZ group and 41 (6.5%) in the 
amlodipine ± HCTZ group experienced a 20% decrease in 
serum potassium levels at any postbaseline visit. No patient 
discontinued due to laboratory abnormalities. Vital signs 
did not reveal any clinically significant trends other than the 
expected improvements in BP.
Discussion
Current treatment guidelines acknowledge the need for 
combination therapy in the majority of patients with 
hypertension, and recommend combination therapy as initial 
treatment for most patients with baseline BP  160/100 mmHg 
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or when total cardiovascular risk is high.2,3 Initial or early use 
of combination therapy using two drugs with complementary 
modes of action may allow patients to reach BP targets 
quicker, with fewer titration steps, and without an increase in 
the side effects associated with higher doses of monotherapy.16 
Moreover, evidence from landmark trials suggests that more 
prompt BP control leads to better clinical outcomes.1
The present study employed algorithms consistent with 
current treatment guidelines, based on patients’ current BP 
level or previous history on antihypertensive drugs. We found 
that initiating therapy earlier with valsartan/HCTZ provided 
superior BP control rates (140/90 mmHg) compared 
with titrating amlodipine monotherapy to its maximum 
dose before adding HCTZ. Significant differences in favor 
Table 2 Least-squares mean changes (seM) from baseline in MssBP and MsDBP by visit
MSSBP MSDBP
Week Valsartan 
strategy*
Amlodipine 
strategy†
P Valsartan 
strategy*
Amlodipine 
strategy†
P
4 −15.3 (0.5) −13.5 (0.5) 0.0029 −8.9 (0.3) −8.0 (0.3) 0.0160
8 −19.6 (0.5) −18.0 (0.5) 0.0078 −10.6 (0.4) −9.8 (0.4) 0.0328
11 −21.4 (0.5) −19.4 (0.5) 0.0006 −12.1 (0.3) −11.5 (0.3) 0.1469
14 −22.3 (0.5) −21.3 (0.5) 0.0630 −12.8 (0.3) −12.1 (0.3) 0.0672
endpoint‡ −21.7 (0.5) −19.6 (0.5) 0.0002 −12.5 (0.3) −11.1 (0.3) 0.0001
Notes: *n = 632 at week 4, 614 at week 8, 603 at week 11, 600 at week 14, and 632 at endpoint. †n = 630 at week 4, 588 at week 8, 553 at week 11, 539 at week 14, and 631 
at endpoint. ‡Week 14 or last observation carried forward value.
Abbreviations: MsDBP, mean sitting diastolic blood pressure; MssBP, mean sitting systolic blood pressure; seM, standard error of the least-squares mean.
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of valsartan ± HCTZ were observed at weeks 8, 11, and 
14 (end of study). The differences were even greater for 
patients who at the start of the study were uncontrolled on 
previous monotherapy. In those patients who were naïve 
to antihypertensive therapy similar BP control rates were 
achieved using either treatment strategy approach. This 
finding may be explained by the greater number of patients 
using monotherapy in the treatment-naïve group compared to 
those in the previous monotherapy group since both regimens 
were associated with few titration steps. The higher incidence 
of peripheral edema with amlodipine ± HCTZ led to more 
frequent treatment discontinuations, resulting in an overall 
lower therapeutic success.
Our results support the use of the valsartan ± HCTZ 
strategy for the treatment of hypertension. This is consistent 
with the well-established role of the RAS in the pathogenesis of 
hypertension.17 Moreover, evidence from large outcomes trials 
(eg, HOPE, ALLHAT, LIFE, and VALUE) has consistently 
demonstrated that a RAS-inhibitor-based approach to 
treatment provides similar or greater cardiovascular and 
organ protection than regimens lacking this component.18 
In contrast, our findings do not support the use of the 
amlodipine ± HCTZ strategy as this regimen was more 
poorly tolerated and yielded inferior BP control rates and BP 
reductions at most clinic visits. This is in line with current 
National Institute for Health and Clinical Excellence (NICE) 
guidance and the ABCD (A = angiotensin-converting enzyme 
inhibitor [ACE-I] or ARBs, B = beta-blockers, C = CCBs, and 
D = thiazide or thiazide-like diuretics) treatment algorithm, 
which suggests that patients starting on a CCB should add 
a RAS inhibitor.19,20 Although the most recent European 
guidelines advocate the use of a CCB/diuretic combination,2 
our results and those of others14 suggest that this is a poor 
recommendation. The combination of an antihypertensive 
agent that blocks the RAS with one that does not is likely 
to be a more effective approach than using two agents that 
both block the RAS (eg, ACE-I+ARB)21,22 or two agents that 
do not affect the RAS (eg, CCB+diuretic). The effectiveness 
of amlodipine monotherapy has been demonstrated in some 
key hypertension outcome studies (eg, TOMHS, VALUE, 
and ALLHAT), but when patients with hypertension cannot 
be effectively controlled with amlodipine monotherapy, it 
would make most sense to use a complementary antihyper-
tensive agent (eg, ACE-I or ARB). Recently, the ASCOT 
and ACCOMPLISH studies demonstrated the importance 
of combining amlodipine with an ACE-I as patients had 
significant reductions in cardiovascular events.23,24
Several previous randomized controlled studies have 
compared valsartan ± HCTZ and amlodipine ± HCTZ 
strategies in patients with essential hypertension, although 
none used the dose and titration schedules described herein. 
The combination of valsartan/HCTZ confers additional 
BP lowering over monotherapy with these agents,8 with 
low doses of this combination (80–160/12.5 mg) providing 
comparable BP reductions to high-dose amlodipine 
monotherapy (10 mg).10–13 Similar overall antihypertensive 
efficacy was demonstrated when a regimen of valsartan 
80 mg o.d. titrated up to valsartan 160 mg/HCTZ 12.5 mg o.d. 
was compared with a regimen of amlodipine 5 mg o.d. titrated 
up to amlodipine 10 mg/HCTZ 12.5 mg o.d.25,26 Lacourcière 
and colleagues conducted a 10-week, forced-titration, 
ambulatory BP monitoring study in which patients with 
stage 2 hypertension started therapy with valsartan 160 mg 
o.d. or amlodipine 5 mg o.d.14 The valsartan arm was titrated 
to valsartan 160 mg/HCTZ 12.5 mg o.d. at two weeks and 
valsartan 320 mg/HCTZ 25 mg o.d. at six weeks, while the 
amlodipine arm was titrated to double-dose at two weeks with 
the addition of HCTZ 25 mg o.d. at six weeks. At 10 weeks, 
the reduction from baseline BP was 3.8/2.7 mmHg greater 
with valsartan/HCTZ than amlodipine/HCTZ (both P  0.01). 
The VALUE outcomes trial reported better BP control 
with an amlodipine-based strategy.27 However, several 
factors related to the study design may have influenced 
the results of VALUE. Patients were not randomized to 
different treatment strategies based on the severity of their 
hypertension or their prior treatment history or response. 
Moreover, the addition of HCTZ was not allowed before two 
months of monotherapy treatment, titration to the high-dose 
valsartan/HCTZ regimen (320 mg/25 mg o.d.) was not an 
option, and patients assigned to the valsartan strategy initiated 
treatment with a suboptimal starting dose (80 mg o.d.).4,28 
The 160-mg dose of valsartan has been shown to be more 
effective than an 80-mg dose in reducing BP from baseline 
Table 3 number (%) of patients with an adverse event of edema, 
by visit
Day or Week Valsartan strategy 
(n = 632)
Amlodipine strategy 
(n = 634)
Day 1 0 2 (1.0)
Week 4 7 (1.1) 88 (13.9)
Week 8 13 (2.1) 132 (20.8)
Week 11 16 (2.5) 147 (23.2)
Week 14 17 (2.7) 153 (24.1)
Notes: Patients were included in the visit occurring first after the onset of edema. 
Patients were counted in all subsequent visits, regardless of whether or not the 
edema had resolved.Vascular Health and Risk Management 2009:5 891
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(14.3/11.1 mmHg vs 11.2/9.0 mmHg) and in providing 
BP control (39.3% vs 22.7%) after up to 8 weeks of therapy, 
with both doses having comparable AE and biochemical 
profiles.4 Numerous ambulatory BP monitoring studies have 
demonstrated that valsartan 160 mg o.d. provides consistent 
reductions in BP throughout the 24-hour interval, with a pres-
ervation of the BP-lowering effect at the end of the dosing 
period.29,30 Further, compared with an 80-mg dose, 160-mg 
of valsartan resulted in more effective inhibition of the RAS 
over the 24-hour dosing period.31,32
Both treatments were well tolerated in the current 
study, with the exception of a relatively high incidence of 
peripheral edema in the amlodipine ± HCTZ group (22.4%) 
versus the valsartan ± HCTZ group (2.2%). Similarly, 
discontinuations due to this AE were higher in the former 
group (7.3% vs 1.0%). Other AEs were reported at a low 
and generally similar incidence with both treatment strategies. 
Peripheral edema is a known side effect of amlodipine. 
A pooled analysis of data from 40 placebo-controlled, 
double-blind studies in which 1,775 patients were treated with 
amlodipine (primarily 5 mg or 10 mg daily) and 1,213 with 
placebo found that the incidence of “edema” was fourfold 
greater with amlodipine than with placebo (P  0.001).33 The 
rates of peripheral edema and associated discontinuations in 
our study (Table 3) were similar to those in Val-Syst study 
(4.8% and 0% for valsartan, respectively; 26.8% and 4.2% 
for amlodipine, respectively).26 Side effects can have a nega-
tive impact on patients’ persistence with antihypertensive 
treatment, which in turn may be associated with adverse clini-
cal outcomes.34 Patients with hypertension who demonstrate 
poor persistence have increased morbidity and mortality and 
higher health care costs. Better tolerated treatment strate-
gies should improve persistence and enable more patients to 
achieve protection against cardiovascular events.
Conclusion
Initiating therapy earlier with valsartan/HCTZ, rather 
than titrating monotherapy to its maximum dose before 
adding a second agent, was superior to amlodipine 
monotherapy or amlodipine ± HCTZ for achieving BP 
control (140/90 mmHg) while avoiding excessive numbers 
of treatment adjustments and maintaining tolerability. 
The incidences of peripheral edema and associated 
discontinuations were greater with amlodipine ± HCTZ.
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